Cargando...
Cost-Utility Analysis: Current Methodological Issues and Future Perspectives
The use of cost–effectiveness as final criterion in the reimbursement process for listing of new pharmaceuticals can be questioned from a scientific and policy point of view. There is a lack of consensus on main methodological issues and consequently we may question the appropriateness of the use of...
Gardado en:
| Main Authors: | , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Frontiers Research Foundation
2011
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3113167/ https://ncbi.nlm.nih.gov/pubmed/21713127 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fphar.2011.00029 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|